From GlobeNewswire:

Celularity Inc. (Nasdaq: CELU) has signed an exclusive U.S. strategic commercialization agreement with BioCellgraft Inc. Celularity will manufacture advanced biomaterial products for BioCellgraft, and BioCellgraft will distribute them in the United States for dental/oral healthcare use. Celularity’s CEO Robert J. Hariri says the deal will provide an important new avenue into the U.S. market for advanced biomaterial products. The press release does include “forward-looking statements.” All statements besides historical facts are “forward-looking statements.” Factors which could cause actual results to differ materially from these forward-looking statements are laid out in the report.



Read more: Celularity Confirms Commercialization Agreement with